Nadim Ahmed, Cullinan Therapeutics CEO

In lat­est turn to au­toim­mune ther­a­pies, Cul­li­nan nabs $280M to join lu­pus space

At Cul­li­nan, im­munol­o­gy is quite lit­er­al­ly the new on­col­o­gy.

The biotech an­nounced Tues­day that it’s ex­pand­ing its pipeline from can­cer to in­clude im­munol­o­gy and chang­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.